Explore Our Diverse Range Of Offerings
From detailed reports to experts services offered in 15+ Industry Domains
Report
Press Release
Blogs
Industry Statistics
Add 2 More Reports For 20% off

Report Overview

Generalized myasthenia gravis (gMG) is a chronic autoimmune neuromuscular disorder characterized by fluctuating weakness of voluntary muscles. According to UCB S.A., Belgium, myasthenia gravis has a prevalence of 100–350 cases per 1 million people. As per generalized myasthenia gravis epidemiology forecast by Expert Market Research, the neuromuscular disease burden is expected to remain clinically significant.

2025

Base Year

2019-2025

Historical Period

2026-2035

Forecast Period

Generalized Myasthenia Gravis – Number of Cases by Year

Read more about this report - Request a Free Sample

Generalized Myasthenia Gravis Epidemiology Forecast Report Coverage

Expert Market Research's “Generalized Myasthenia Gravis Epidemiology Forecast Report 2026-2035” offers comprehensive information on the prevalence and demographics of generalized myasthenia gravis. It projects the future incidence and prevalence rates of generalized myasthenia gravis cases across various populations. The study covers age, gender, and type as major determinants of the generalized myasthenia gravis population. The report highlights patterns in the prevalence of generalized myasthenia gravis over time and projects future trends based on multiple variables.

The report provides a comprehensive overview of the disease, as well as historical and projected data on the epidemiology of generalized myasthenia gravis in the 8 major markets.

Regions Covered

  • United States
  • Germany
  • France
  • Italy
  • Spain
  • United Kingdom
  • Japan
  • India

Generalized Myasthenia Gravis Understanding: Disease Overview

Generalized myasthenia gravis (gMG) is a chronic autoimmune disorder of the neuromuscular junction in which pathogenic antibodies impair communication between nerves and skeletal muscles, resulting in fluctuating, fatigable muscle weakness. The condition commonly affects ocular, bulbar, limb, and respiratory muscles and can substantially impair physical functioning. MG is broadly classified into ocular and generalized forms based on the distribution of weakness. Generalized disease may be associated with antibodies against the acetylcholine receptor (AChR), muscle-specific kinase (MuSK), or other neuromuscular junction proteins.

Key Report Insights

Parameter

Insight

Largest Patient Pool

United States

Fastest Growing Country

India

High-Risk Population

MG epidemiology varies by age and sex; US data show higher prevalence among older adults and higher rates among younger women compared with age-matched men.

Key Diagnostic Method

Serologic antibody testing and neurophysiologic testing; diagnosis generally integrates clinical assessment with AChR/MuSK antibody testing and electrodiagnostic evaluation.

Major Risk Factor

Autoimmune susceptibility. MG is primarily an autoimmune disorder, with genetic and environmental factors contributing to disease susceptibility.

Major gap in the market

Underdiagnosis and delayed diagnosis. Mild and atypical cases may be missed, while geographic differences in case finding and diagnostic practices contribute to variation in reported epidemiology.

Generalized Myasthenia Gravis Epidemiology Perspective

The generalized myasthenia gravis epidemiology division offers information on the patient pool from history to the present as well as the projected trend for each of the 8 major markets. Expert Market Research provides both current and predicted trends for the generalized myasthenia gravis epidemiology scenario by examining a wide range of studies. Additionally, the report covers the diagnosed patient pool for generalized myasthenia gravis and their trends. The data is broken down into specific categories, such as total prevalent cases in males and females, and total diagnosed cases across different age groups and patient pools.

Epidemiology Segment

Key Insights

Diagnosed Prevalent Cases of the Disease

According to UCB S.A., Belgium, myasthenia gravis has a global prevalence of 100–350 cases per 1 million people.

Gender-Specific Cases of the Disease

As per AmeriPharma, generalized myasthenia gravis affects women more frequently than men, with a reported female-to-male ratio of approximately 2:1 among patients with myasthenia gravis.

Age-Specific Cases of the Disease

According to Bionews, Inc., patients developing generalized myasthenia gravis at 65 years or older may experience a more aggressive initial disease course. MJH Life Sciences reports a median onset age of 59 years in Japan.

Ethnicity-Wise Cases of the Disease

Epidemiological patterns vary across populations, reflecting differences in age distribution, disease presentation, and the proportion of patients developing generalized disease. The provided data indicate substantial geographic variation in reported disease burden.

Mortality and Survival Analysis of the Disease

According to UCB S.A., 15–20% of people living with generalized myasthenia gravis experience myasthenic crisis, which can lead to respiratory failure. Disease severity typically increases during the first two years after diagnosis.

Type-Specific Disease Burden and Epidemiology Analysis

Disease Type

Prevalence

AChR-Positive gMG

AChR-positive generalized myasthenia gravis represents the predominant antibody-defined subtype, accounting for a significant share of gMG cases, based on the provided data.

MuSK-Positive gMG

MuSK-positive gMG represents a less common subtype and is characterized by antibodies targeting muscle-specific kinase. It is associated with a distinct disease profile, particularly involving bulbar and respiratory muscle weakness.

LRP4-Positive gMG

LRP4-positive gMG is an antibody-defined subtype associated with antibodies targeting low-density lipoprotein receptor-related protein 4. It represents an additional immunological subgroup within the broader generalized myasthenia gravis population.

Seronegative gMG

Seronegative gMG represents patients with generalized disease in whom standard antibody testing does not identify detectable antibodies. This subtype contributes to the broader gMG population despite the absence of routinely detected antibodies.

Generalized Myasthenia Gravis – Number of Cases by Country

Read more about this report - Request a Free Sample

Country-wise Generalized Myasthenia Gravis Epidemiology

The generalized myasthenia gravis epidemiology data and findings for the United States, Germany, Spain, Italy, France, the United Kingdom, Japan, and India are also provided in the epidemiology section.

Country

Key Insights

United States

According to Alexion Pharmaceuticals, Inc., generalized myasthenia gravis affects approximately 37 people per 100,000 in the United States. The reported burden indicates a measurable patient population despite the condition being classified as rare.

Germany

According to AstraZeneca, Germany is included among the five European countries with an estimated combined 82,500 people diagnosed with generalized myasthenia gravis. Approximately 66,000 patients across these countries are reported to be AChR-positive.

France

As per AstraZeneca, France forms part of the five-country European population in which approximately 82,500 people are estimated to have generalized myasthenia gravis. A substantial proportion, approximately 66,000 patients, are reported as AChR-positive across these countries.

Italy

According to AstraZeneca, Italy is included within the European five-country population with an estimated 82,500 people diagnosed with generalized myasthenia gravis. The combined population includes approximately 66,000 AChR-positive patients.

Spain

As per AstraZeneca, Spain is among the five European countries with an estimated combined generalized myasthenia gravis population of 82,500 people. Approximately 66,000 patients across Germany, France, the United Kingdom, Italy, and Spain are AChR-positive.

United Kingdom

According to AstraZeneca, the United Kingdom is included in the five European countries with an estimated 82,500 people diagnosed with generalized myasthenia gravis. Approximately 66,000 patients across these countries are reported to be AChR-positive.

Japan

According to MJH Life Sciences, a 2018 nationwide epidemiological survey estimated approximately 29,000 people with myasthenia gravis in Japan, corresponding to a prevalence of 23.1 per 100,000. The median age at onset was 59 years, with approximately 80% of cases generalized.

India

The epidemiological pattern of generalized myasthenia gravis in India is characterized by the broader disease burden, age distribution, and gender patterns observed in myasthenia gravis. The available information supports consideration of generalized disease within the overall epidemiological assessment.

Key Market Gaps, Untapped Opportunities, and Emerging Growth Areas in the Regional Disease Epidemiology Landscape

The regional epidemiology of generalized myasthenia gravis presents opportunities to improve case identification, particularly among patients with mild, fluctuating, or atypical symptoms. Variations in reported incidence and prevalence across the United States, European countries, Japan, and India partly reflect differences in case ascertainment, diagnostic tools, healthcare access, and epidemiologic methodology.

Generalized Myasthenia Gravis: Treatment Overview

Generalized myasthenia gravis treatment aims to improve neuromuscular transmission, control autoimmune activity, reduce symptoms, and prevent exacerbations and myasthenic crisis. Symptomatic management commonly includes acetylcholinesterase inhibitors such as pyridostigmine, while corticosteroids and steroid-sparing immunosuppressants are used for longer-term disease control. Patients with severe or refractory disease may receive targeted therapies, including complement inhibitors or agents directed against the neonatal Fc receptor. Intravenous immunoglobulin and plasma exchange are used for acute worsening or myasthenic crisis. Thymectomy may be considered in selected patients, particularly those with thymoma or AChR-positive disease.

Key Questions Answered

  • What is the current and projected burden of generalized myasthenia gravis across the 8 major markets?
  • Which countries across the 8 major markets account for the highest generalized myasthenia gravis patient populations and fastest growth rates?
  • What is the diagnosed versus undiagnosed patient population of generalized myasthenia gravis across key countries in the 8 major markets?
  • Which countries demonstrate the largest gaps in screening, early diagnosis, and disease awareness of generalized myasthenia gravis across the 8 major markets?
  • What are the major drivers contributing to the increasing burden of generalized myasthenia gravis across the 8 major markets?
  • How do major comorbidities and risk factors influence generalized myasthenia gravis epidemiology trends across the 8 major markets?
  • What are the regional trends in advanced disease progression, treatment uptake, and patient management of generalized myasthenia gravis across the 8 major markets?
  • Which patient segments represent the highest unmet clinical need in the generalized myasthenia gravis landscape across the 8 major markets?
  • Which therapeutic areas linked to generalized myasthenia gravis are expected to witness the strongest growth opportunities across the 8 major markets?
  • How is the generalized myasthenia gravis epidemiology landscape expected to evolve over the next 5 to 10 years across the 8 major markets?
  • Which countries across the 8 major markets offer the most attractive market opportunities based on generalized myasthenia gravis epidemiology and healthcare infrastructure?
  • Which epidemiological trends are expected to influence future drug development and market access strategies for generalized myasthenia gravis across the 8 major markets?

Scope of the Generalized Myasthenia Gravis Epidemiology Report

  • The report covers a detailed analysis of signs and symptoms, causes, risk factors, pathophysiology, diagnosis, treatment options, and classification/types of generalized myasthenia gravis based on several factors.
  • Generalized Myasthenia Gravis Epidemiology Forecast Report covers data for the eight major markets (the US, France, Germany, Italy, Spain, the UK, Japan, and India).
  • The generalized myasthenia gravis report helps to identify the patient population, and the unmet needs are highlighted along with an assessment of the disease's risk and burden.

Related Reports

Myasthenia Gravis Epidemiology

Myasthenia Gravis Pipeline

*While we strive to always give you current and accurate information, the numbers depicted on the website are indicative and may differ from the actual numbers in the main report. At Expert Market Research, we aim to bring you the latest insights and trends in the market. Using our analyses and forecasts, stakeholders can understand the market dynamics, navigate challenges, and capitalize on opportunities to make data-driven strategic decisions.*

Report Summary

Explore our key highlights of the report and gain a concise overview of key findings, trends, and actionable insights that will empower your strategic decisions.

Key Highlights of the Report

Please note that the figures mentioned in the description serve as estimates and may vary from the actual figures presented in the final report.

Report Features

Details

Base Year

2025

Historical Period

2019-2025

Forecast Period

2026-2035

Epidemiology Statistics Provided

  • Diagnosed Prevalent Cases
  • Type-Specific Cases
  • Gender-Specific Cases
  • Age-Specific Cases

Segmentation Provided

  • Epidemiology by Age Group
  • Epidemiology by Gender
  • Epidemiology by Type of Disease
  • Epidemiology by Region

Geographies Covered

  • United States
  • Germany
  • Italy
  • France
  • Spain
  • United Kingdom
  • Japan
  • India

Datasheet

10 % Off

USD

2,699

2,429

Single User License

10 % Off

USD

4,299

3,869

Five User License

15 % Off

USD

5,799

4,949

Corporate License

15 % Off

USD

6,999

5,949

Datasheet

One User

USD 2,699

USD 2,429

tax inclusive*

  • Selected Segments
  • Printing Restrictions
  • Excel Spreadsheet Delivered via Email
  • Full Report
  • Periodic Updates
  • Post Sales Analysts Support
  • Unlimited Prints

Single User License

One User

USD 4,299

USD 3,869

tax inclusive*

  • All Segments
  • Printing Restrictions
  • PDF Delivered via Email
  • Custom Report Layout
  • Post Sales Analysts Support
  • Periodic Updates
  • Unlimited Prints

Five User License

Five User

USD 5,799

USD 4,949

tax inclusive*

  • All Segments
  • Five Prints Available
  • PDF Delivered via Email
  • Limited Free Customization
  • Post Sales Analyst Support
  • Custom Report Layout
  • Periodic Updates
  • Unlimited Prints

Corporate License

Unlimited Users

USD 6,999

USD 5,949

tax inclusive*

  • All Segments
  • Unlimited Prints Available
  • PDF & Excel Delivery via Email
  • Limited Free Customization
  • Post Sales Analysts Support
  • Discount On Next Update
  • Custom Report Layout

*Please note that the prices mentioned below are starting prices for each bundle type. Kindly contact our team for further details.*

Bundle Type

Flash Bundle

20% OFF Number of Reports: 3

Small Business Bundle

25% OFF Number of Reports: 5

Growth Bundle

30% OFF Number of Reports: 8

Enterprise Bundle

35% OFF Number of Reports: 10
Overview
  • Life Time Access
  • Analyst Support Related to Report
  • PDF Version of the Report
  • Complimentary Excel Data Set
  • Free Analyst Hours
  • Complimentary Free 1 Month Subscription to Trade Data Base
  • Complimentary One Month Subscription to Price Database (Chemicals only)
  • Complimentary PPT Version of the Report
  • Complimentary License Upgrade
  • Complimentary Power BI Dashboards
  • Life Time Access
  • Analyst Support Related to Report
  • PDF Version of the Report
  • Complimentary Excel Data Set
  • Free Analyst Hours - 50 Hours
  • Complimentary Free 1 Month Subscription to Trade Data Base
  • Complimentary One Month Subscription to Price Database (Chemicals only)
  • Complimentary PPT Version of the Report
  • Complimentary License Upgrade
  • Complimentary Power BI Dashboards
  • Life Time Access
  • Analyst Support Related to Report
  • PDF Version of the Report
  • Complimentary Excel Data Set
  • Free Analyst Hours - 80 Hours
  • Complimentary Free 1 Month Subscription to Trade Data Base
  • Complimentary One Month Subscription to Price Database (Chemicals only)
  • Complimentary PPT Version of the Report
  • Complimentary License Upgrade
  • Complimentary Power BI Dashboards
  • Life Time Access
  • Analyst Support Related to Report
  • PDF Version of the Report
  • Complimentary Excel Data Set
  • Free Analyst Hours - 100 Hours
  • Complimentary Free 1 Month Subscription to Trade Data Base
  • Complimentary One Month Subscription to Price Database (Chemicals only)
  • Complimentary PPT Version of the Report
  • Complimentary License Upgrade
  • Complimentary Power BI Dashboards

*Please note that the prices mentioned below are starting prices for each bundle type. Kindly contact our team for further details.*

Flash Bundle

Number of Reports: 3

20%

tax inclusive*

  • 3 Reports Included
  • Life Time Acess
  • Analyst Support Related to Report
  • PDF Version of the Report
  • Free 1 Month Subscription to Trade Data Base
  • 1 Month Subscription to Price Database (Chemicals only)
  • Complimentary Excel Data Set
  • PPT Version of the Report
  • Power BI Dashboards
  • License Upgrade
  • Free Analyst Hours

Small Business Bundle

Number of Reports: 5

25%

tax inclusive*

  • 5 Reports Included
  • Life Time Acess
  • Analyst Support Related to Report
  • PDF Version of the Report
  • Complimentary Excel Data Set
  • Free Analyst Hours - 50 Hours
  • Free 1 Month Subscription to Trade Data Base
  • 1 Month Subscription to Price Database (Chemicals only)
  • Complimentary Excel Data Set
  • PPT Version of the Report
  • Power BI Dashboards
  • License Upgrade

Growth Bundle

Number of Reports: 8

30%

tax inclusive*

  • 8 Reports Included
  • Life Time Acess
  • Analyst Support Related to Report
  • PDF Version of the Report
  • Complimentary Excel Data Set
  • Free Analyst Hours - 50 Hours
  • Free 1 Month Subscription to Trade Data Base
  • 1 Month Subscription to Price Database (Chemicals only)
  • License Upgrade
  • Free Analyst Hours - 80 Hours
  • Power BI Dashboards

Enterprise Bundle

Number of Reports: 10

35%

tax inclusive*

  • 10 Reports Included
  • Life Time Acess
  • Analyst Support Related to Report
  • PDF Version of the Report
  • Complimentary Excel Data Set
  • Free Analyst Hours - 50 Hours
  • Free 1 Month Subscription to Trade Data Base
  • 1 Month Subscription to Price Database (Chemicals only)
  • License Upgrade
  • Power BI Dashboards
  • Free Analyst Hours - 100 Hours

How To Order

This is a collaborative report by Vishakha Agrawal reflecting perspectives and research-driven insights from Expert Market Research.

Our step-by-step guide will help you select, purchase, and access your reports swiftly, ensuring you get the information that drives your decisions, right when you need it.

License Type

Select License Type

Choose the right license for your needs and access rights.

shopping cart

Click on ‘Buy Now’

Add the report to your cart with one click and proceed to register.

Bookmark Icon

Select Mode of Payment

Choose a payment option for a secure checkout. You will be redirected accordingly.

Strategic Solutions for Informed Decision-Making

Connect For More Information

Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.

Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.

We employ meticulous research methods, blending advanced analytics and expert insights to deliver accurate, actionable industry intelligence, staying ahead of competitors.

Our skilled analysts offer unparalleled competitive advantage with detailed insights on current and emerging markets, ensuring your strategic edge.

We offer an in-depth yet simplified presentation of industry insights and analysis to meet your specific requirements effectively.

We’re here to help answer any questions about our products and services.

Contact us